News

This strategic initiative aims to unlock the value of subsidiaries through business restructuring and optimize the overall operational efficiency of the group. After the spin-off is completed, the newly established aerospace company will operate as an independent entity, with a clearer strategic focus and a more flexible capital structure. The transaction is subject to regulatory approval and is expected to have a profound impact on the company’s future market positioning.

The project has made significant progress, and the company expects to complete the selection of clinical candidate drugs in the second half of 2026. This important milestone marks a key step forward for the company in the field of gene therapy research and development in neuroscience. The identification of candidate drugs will lay a solid foundation for subsequent clinical development and is expected to bring new hope for treatment to Huntington's disease patients.

This dividend adjustment reflects the company's robust financial position and ongoing commitment to shareholder returns. Although the dividend increase is modest, it demonstrates management's confidence in maintaining a stable dividend policy amid a complex market environment. This decision is typically viewed by the market as a signal of healthy corporate cash flow and optimism regarding future earnings prospects.